Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Ipilimumab + Sargramostim for Advanced Melanoma
Recruiting1 awardPhase 2 & 3
Dayton, Ohio
This trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.